Lv11
48 积分 2024-09-17 加入
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
1小时前
求助中
Indirect Comparison of Sintilimab and Other PD-L1 Inhibitors for First-Line Treatment of Non-Squamous Non-Small-Cell Lung Cancer
1个月前
已完结
Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
2个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
2个月前
已完结
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
2个月前
已完结
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial
2个月前
已完结
eVOLVE-Cervical (GOG-3092/ENGOT-cx19/GEICO133-C): A prospective phase III study of volrustomig versus placebo after definitive chemoradiation among women with high-risk, locally advanced cervical cancer
2个月前
已关闭
Identification of biomarkers associated with macrophage polarization in diabetic cardiomyopathy based on bioinformatics and machine learning approaches
3个月前
已完结
Re-Treatment With The Immune Checkpoint Inhibitor Cadonilimab In Patients With Cervical Cancer Who Progressed After Anti-PD-1 Therapy: A Real-World Study
3个月前
已完结
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
